NMN and NR Cost Reports: What People Actually Pay for NAD+ Precursors in 2026

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR, sold as the branded product Tru Niagen by ChromaDex) are both over-the-counter dietary supplements marketed as NAD+ precursors. Neither is an FDA-approved drug, and neither has an FDA-recognized medical indication. This matters for cost because it means there is no standardized dosage, no mandated purity testing, and no regulated pricing benchmark the way there would be for a prescription product.

The direct answer: based on current retailer and marketplace listings as of mid-2026, NMN generally costs somewhere between $0.50 and $2.00 per day depending on dose and brand, and Tru Niagen-brand NR generally costs $1.10 to $1.60 per day at a standard 300 mg dose. Neither is covered by insurance, Medicare, Medicaid, or FSA/HSA plans because both are classified as dietary supplements rather than drugs. These figures come from publicly visible retailer pricing and recurring patterns in forum discussion, not from an independent, controlled pricing audit, so treat them as a directional range rather than a fixed number.

How much does NMN cost, and what does the price actually buy?

Bulk NMN powder is consistently the cheapest format reported across longevity and supplement forums, generally landing below $0.65 per day at a 1,000 mg dose when purchased from direct-to-consumer sellers. The tradeoff is that dosing precision depends on the buyer owning a milligram-accurate scale, and powder purity is harder to verify without a published Certificate of Analysis (COA) from a named third-party lab.

Capsule NMN from brands that publish COAs tends to cost more, commonly $30 to $60 for a 30-day supply at 500 mg daily and roughly double that at 1,000 mg daily. Sublingual and liposomal forms carry a further premium, often 20 to 40% above standard capsules, on the claim that bypassing first-pass digestion improves absorption. As of mid-2026, no published human pharmacokinetic study directly compares sublingual versus oral NMN absorption in a way that has been independently verified for this article, so that bioavailability claim should be treated as a marketing claim requiring verification rather than an established fact.

The core point for buyers: at equivalent doses, price differences between NMN brands mostly reflect testing, packaging, and brand overhead rather than a different active ingredient. The molecule itself is not patent-protected by any single manufacturer, which is part of why NMN pricing varies more widely than NR pricing.

How does NR pricing compare, and why does it run higher?

NR sold as Tru Niagen is a more consolidated market than NMN. ChromaDex holds patents covering nicotinamide riboside chloride, which limits how many manufacturers can compete on price for that specific salt form. A 30-day supply of Tru Niagen at 300 mg per day generally retails for $33 to $48, narrowing to roughly $0.95 to $1.10 per day with subscription or bundle pricing and running higher, up to roughly $1.60 per day, through some third-party retailers.

On a per-milligram basis, NR tends to cost more than commodity NMN powder. At the doses people actually take, this gap narrows because typical NR doses (300 mg) are lower than typical self-reported NMN doses (500 to 1,000 mg), but NR generally still runs 30 to 80% more expensive per day. Buyers who cite price as the deciding factor between NMN and NR are choosing a less patent-constrained, more variably-tested market (NMN) over a more consolidated, single-manufacturer market (NR) that has a longer track record of published human dosing trials at its retail dose.

What does the clinical evidence actually support, and at what dose?

This is the section most likely to be misread, so it is worth being precise.

NR has the larger body of small, published human trials examining whether oral supplementation raises blood or muscle NAD+ metabolites in healthy or older adults, generally using doses in the 300 mg to 1,000 mg per day range over periods of weeks. NMN has fewer human trials, but the most frequently cited one is a study in postmenopausal women with prediabetes that used 250 mg NMN daily for 10 weeks and reported improved skeletal muscle insulin sensitivity measured by hyperinsulinemic-euglycemic clamp. That trial's dose, 250 mg, is lower than the 500 to 1,000 mg most self-experimenters report taking on forums.

No published randomized controlled trial establishes that doubling or quadrupling that dose produces a better clinical outcome in humans. The gap between the trial dose and the self-experimentation dose is a real evidence gap, not a minor technicality: cost scales with dose, so someone paying for 1,000 mg daily is paying roughly four times the daily cost of the studied protective dose without trial evidence that the extra spend buys additional benefit. Because the specific PubMed identifiers historically attached to these trials in secondary sources are frequently mismatched to the wrong paper, any reader relying on a specific citation for these findings should verify it directly against PubMed or the original journal before treating it as settled, rather than trusting a link pulled from a summary article.

The Endocrine Society and other guideline-issuing bodies have not published formal dosing guidance for NMN or NR supplementation in any population. That absence is itself informative: there is no accountable clinical body currently recommending a specific dose, which means every dose decision a consumer makes is currently a personal judgment call, not a guideline-backed one.

An evidence-review framework: what different sources of "it worked" actually tell you

Forum reviews, retailer pricing, lab test results, and clinical trials are not interchangeable evidence, even though they get cited interchangeably in NMN and NR discussions. This framework separates what each source type can and cannot support, and what the next verification step would be before acting on it.

The practical decision rule this produces: price differences between products tell you about manufacturing and testing costs, not about clinical benefit. Clinical trial evidence tells you about a specific dose in a specific population over a specific number of weeks, and does not automatically justify a higher self-chosen dose. If a forum claim and a trial finding conflict, the trial finding at its studied dose and population is the more reliable anchor, and everything outside that dose and population is unverified extrapolation.

What do forum and review reports actually show?

A read of ongoing discussion on NMN- and longevity-focused forums over the past two years shows a recurring pattern rather than a single consistent number: buyers self-sort into a lower-cost tier (bulk powder, roughly $15 to $30 per month, with purity as the main stated risk), a mid-cost tier (COA-verified capsules or subscription-priced Tru Niagen, roughly $30 to $60 per month), and a higher-cost tier (sublingual/liposomal forms, NMN-NR stacks, or clinic-dispensed NMN bundled with consultations, often $60 to $150+ per month). These figures are drawn from patterns in public forum discussion and retailer listings rather than from a controlled survey, and forum participants are not a representative sample: they skew toward younger, cost-conscious, research-active buyers, so their reported experience may not reflect typical consumer behavior or typical product quality across the whole market.

Specific first-person quotations attributed to named platforms cannot be verified for this article and have been removed rather than reproduced, because an unverifiable quotation attached to a health product carries more risk than value. The general pattern, that cost-conscious users gravitate to bulk powder and cite purity uncertainty as the tradeoff, is consistent across multiple threads even without a single quotable line to anchor it.

Are there hidden costs beyond the supplement price?

Yes, for people who want to know whether the supplement is doing anything measurable.

NAD+ testing. Standard clinical lab panels (through services like Quest or Labcorp) do not measure intracellular NAD+ directly. Specialty NAD+ testing services exist outside mainstream clinical labs and are reported to cost roughly $150 to $250 per test; testing two to four times a year would add a few hundred to around a thousand dollars annually. This is a real cost some users take on, but it is worth stating plainly: even where a test shows a biomarker changed, that does not establish a health outcome changed.

Storage. NMN is reported to be sensitive to heat and humidity, and some manufacturers recommend refrigeration after opening. Bulk purchases intended to save money can lose potency if stored poorly, which undercuts the savings; a lab-grade stability comparison for a specific product should be checked against that product's own documentation rather than assumed.

Clinic-dispensed NMN. Some longevity clinics dispense NMN bundled with consultations and blood work at a higher monthly price than direct-to-consumer purchase. The premium there is for physician oversight and monitoring, not a different compound, though whether that monitoring changes outcomes has not been established in published trials.

How does this compare to insurance, FSA, and HSA rules, and to other longevity spending?

Neither NMN nor NR is covered by any commercial insurance plan, Medicare, or Medicaid, and neither qualifies for FSA or HSA reimbursement under current IRS rules, because both are classified as dietary supplements rather than FDA-approved drugs. A physician's letter of medical necessity does not change this classification. This is a stable regulatory fact as of 2026 and would only change with a change in FDA drug status, which has not occurred for either compound as of this writing (see FDA's dietary supplements overview, linked below).

For context, prescription off-label metformin, rapamycin, and prescription NAD+ IV infusions occupy different price points and different regulatory categories entirely (prescription drugs requiring a physician, versus supplements requiring none). Comparing their prices to NMN or NR price is useful for budgeting but not for judging relative evidence quality, since prescription status and supplement status reflect different regulatory pathways, not different levels of proof of benefit.

What should buyers verify before paying for a specific product?

• Does the brand publish a full Certificate of Analysis, including the testing lab's name and batch number, rather than a generic purity claim?
• Is the testing lab independent and named, or is "third-party tested" used without naming who tested it?
• Does the price reflect dose (mg per day), not just bottle price, so you can compare cost per milligram across brands?
• Is the dose you're considering close to a dose that has actually been studied in a published human trial, or well above it with no trial support?
• Are you paying extra for a delivery format (sublingual, liposomal) based on a bioavailability claim that has independent verification, or based on marketing language alone?

What is established, what is plausible, and what is not established

Established: NMN and NR are unregulated dietary supplements with no FDA-approved medical indication and no insurance or FSA/HSA eligibility. Small human trials have shown that oral NMN and NR supplementation can raise blood or muscle NAD+-related metabolites in specific study populations at specific doses over weeks. Price varies substantially by format, brand, and testing rigor, and much of that variation reflects manufacturing and verification costs rather than the underlying molecule.

Plausible but unproven: That raising blood NAD+ metabolites translates into a durable health or longevity benefit in generally healthy adults. That sublingual or liposomal delivery meaningfully improves absorption over standard oral capsules. That doses above those used in published trials (commonly 250 mg to 1,000 mg depending on the study) produce additional benefit proportional to their additional cost.

Not established: Any anti-aging or longevity-extension effect in humans from either compound. A guideline-recommended dose from any accountable clinical body. Long-term safety data at the higher doses commonly self-reported on forums.